Endocannabinoid System Biomarkers in Alzheimer's Disease

Cannabis Cannabinoid Res. 2023 Feb;8(1):77-91. doi: 10.1089/can.2022.0151. Epub 2022 Nov 17.


Background: Alterations in the endocannabinoid system (ES) have been described in Alzheimer's disease (AD) pathophysiology. In the past years, multiple ES biomarkers have been developed, promising to advance our understanding of ES changes in AD. Discussion: ES biomarkers, including positron emission tomography with cannabinoid receptors tracers and biofluid-based endocannabinoids, are associated with AD disease progression and pathological features. Conclusion: Although not specific enough for AD diagnosis, ES biomarkers hold promise for prognosis, drug-target engagement, and a better understanding of the disease. Here, we summarize currently available ES biomarker findings and discuss their potential applications in the AD research field.

Keywords: Alzheimer's disease; biomarkers; dementia; endocannabinoid.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / pathology
  • Biomarkers
  • Disease Progression
  • Endocannabinoids
  • Humans
  • Positron-Emission Tomography
  • Receptors, Cannabinoid


  • Endocannabinoids
  • Receptors, Cannabinoid
  • Biomarkers